Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316143 | 0.82 | MEN1 (0.64) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL1491259 | 0.82 | MEN1 (0.64) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL392828 | 0.82 | MEN1 (0.64) | MEN1KMT2ARAB9APAX8PDE10A | |
| Hydrochloric Acid SCHEMBL28105348 | 0.81 | MEN1 (0.62) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL20476787 | 0.81 | KMT2A (0.71) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL18497237 | 0.79 | KMT2A (0.78) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL25259337 | 0.78 | PAX8 (0.60) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL18497242 | 0.78 | KMT2A (1.00) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL28062114 | 0.78 | PAX8 (0.60) | MEN1KMT2ARAB9APAX8PDE10A | |
| SCHEMBL31193452 | 0.78 | PAX8 (0.60) | MEN1KMT2ARAB9APAX8PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121021384-A | N- (tert-butoxycarbonyl) -S- (3-nitro-2-pyridylthio) -L-cysteine and preparation method and application thereof | 四川普康药业有限公司 | 2025-11-28 | — | — | CN | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| CN-104086540-B | Preparation method for 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | 安那迪斯药品股份有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
| US-RE34165-E | Pentapeptide immunoregulators | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0166612-B1 | POTENT THYMOPENTIN ANALOGS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0146266-B1 | ENZYME-RESISTANT IMMUNOMODULATORY PEPTIDES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-05-22 | — | — | EP | disclosed |
| US-4629723-A | IMMUNOREGULATING PEPTIDES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0166612-A2 | Potent thymopentin analogs | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0165033-A2 | Conformationally restricted thymopentin-like compounds | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4547489-A | OLIGOPEPTIDE HAVING IMMUNOREGULATORY ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0146266-A2 | Enzyme-resistant immunomodulatory peptides | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-06-26 | — | — | EP | disclosed |
| US-4505853-A | GLANDULAR DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | MEN1 1280/4885KMT2A 86/4885RAB9A 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.